{"id":954725,"date":"2026-04-27T07:30:10","date_gmt":"2026-04-27T11:30:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/"},"modified":"2026-04-27T07:30:10","modified_gmt":"2026-04-27T11:30:10","slug":"ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/","title":{"rendered":"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., April  27, 2026  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026.<\/p>\n<p>\n        <strong>Upcoming Investor Conferences<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>\n        <strong>Bank of America Health Care Conference 2026<\/strong>:<br \/>Date: Tuesday, May 12, 2026<br \/>Fireside Chat: 3:40 \u2013 4:10 PM PDT<br \/>Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO<br \/>Location: Las Vegas, NV<\/p>\n<p>\n        <strong>Stifel 2026 Virtual Ophthalmology Forum<\/strong>:<br \/>Date: Tuesday, May 26, 2026<br \/>Fireside Chat: 2:30 \u2013 2:55 PM EDT<br \/>Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO<br \/>Location: Virtual<\/p>\n<p>A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.<\/p>\n<p>\n        <strong>Upcoming Scientific Conferences<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>\n        <strong>Eyecelerator @ ARVO 2026:<\/strong> May 1, 2026<br \/>Denver, CO<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Presentation: Ocular Therapeutix: Retina Experience Redefined<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Presentation Date\/Time: Friday, May 1, 2026, 2:18 \u2013 2:23 PM MDT<br \/>Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix<\/p>\n<p>\n        <strong>ARVO 2026 Annual Meeting<\/strong>: May 3 &#8211; 7, 2026<br \/>Denver, CO<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Phase 3 SOL-1 Trial Results<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Presentation Date\/Time:\u00a0Tuesday, May 5, 2026, 1:15 \u2013 1:30 PM MDT<br \/>Presenter: Patricio G. Schlottmann, MD<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Poster Title: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Session Date\/Time:\u00a0Thursday, May 7, 2026, 8:00 \u2013 9:45 AM MDT<br \/>Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Poster Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Session Date\/Time:\u00a0Thursday, May 7, 2026, 8:00 \u2013 9:45 AM MDT<br \/>Presenter: Christina Y. Weng, MD, MBA<\/p>\n<p>\n        <strong>Retina World Congress (RWC) 2026<\/strong>: May 14 &#8211; 17, 2026<br \/>Fort Lauderdale, FL<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Presentation Title: Ocular Therapeutix: Retina Experience Redefined<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Presentation Date\/Time:\u00a0Thursday, May 14, 2026, 8:15 \u2013 8:20 AM EDT<br \/>Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Presentation Title: Update on Latest TKI data from the OTX-TKI program<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Presentation Date\/Time:\u00a0Friday, May 15, 2026, 4:30 \u2013 4:35 PM EDT<br \/>Presenter: Dilsher S. Dhoot, MD<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Symposium Date\/Time:\u00a0Friday, May 15, 2026, 7:15 \u2013 8:15 PM EDT<br \/>Presenters: Patricio G. Schlottmann, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD<\/p>\n<p>\n        <strong>The Royal College of Ophthalmologists Annual Congress 2026<\/strong>: May 18 &#8211; 20, 2026<br \/>Manchester, UK<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>Symposium Date\/Time:\u00a0Tuesday, May 19, 2026, 12:30 \u2013 1:30 PM BST<br \/>Presenters: Adnan Tufail, MBBS, MD, FRCOphth; Darius M. Moshfeghi, MD; Dilsher S. Dhoot, MD<\/p>\n<p>Exact medical conference presentation times may be subject to change.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.<\/p>\n<p>Follow the Company on its website, LinkedIn, or X.<\/p>\n<p>DEXTENZA<sup>\u00ae<\/sup> is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FxWd9VPOgNnFW0S1j6Z6P2k22cmXL6icP1DQ1qp4Hs8Yo2GYzskRA0VQ-mv08r8fQS_7zMkZl0ZrXhJuYDvqqOCaghfXM20G11PFzBSFv2I=\" rel=\"nofollow\" target=\"_blank\">bslattery@ocutx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjBlNzY5OWUtZjgyZC00Njk1LTgzYmYtYWNmOWQ2OTliYTdmLTEwMjI2MjktMjAyNi0wNC0yNy1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences : Bank of America Health Care Conference 2026:Date: Tuesday, May 12, 2026Fireside Chat: 3:40 \u2013 4:10 PM PDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Las Vegas, NV Stifel 2026 Virtual Ophthalmology Forum:Date: Tuesday, May 26, 2026Fireside Chat: 2:30 \u2013 2:55 PM EDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954725","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences : Bank of America Health Care Conference 2026:Date: Tuesday, May 12, 2026Fireside Chat: 3:40 \u2013 4:10 PM PDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Las Vegas, NV Stifel 2026 Virtual Ophthalmology Forum:Date: Tuesday, May 26, 2026Fireside Chat: 2:30 \u2013 2:55 PM EDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T11:30:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences\",\"datePublished\":\"2026-04-27T11:30:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/\"},\"wordCount\":616,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=\",\"datePublished\":\"2026-04-27T11:30:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences - Market Newsdesk","og_description":"BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences : Bank of America Health Care Conference 2026:Date: Tuesday, May 12, 2026Fireside Chat: 3:40 \u2013 4:10 PM PDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Las Vegas, NV Stifel 2026 Virtual Ophthalmology Forum:Date: Tuesday, May 26, 2026Fireside Chat: 2:30 \u2013 2:55 PM EDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and &hellip; Continue reading \"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-27T11:30:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences","datePublished":"2026-04-27T11:30:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/"},"wordCount":616,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/","name":"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=","datePublished":"2026-04-27T11:30:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzI1NCM3NTY2NjU1IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Participate in May Scientific and Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954725"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954725\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}